Introduction
Lunit is a Seoul-based medical AI company founded in 2013 that builds cancer detection and biomarker products across radiology and pathology. Brandon Beomseok Suh serves as chief executive officer, a role confirmed on Lunit’s governance and about pages reviewed in July 2026. Lunit is publicly listed on Korea’s KOSDAQ exchange and describes its mission as conquering cancer through AI, from screening through research and development.
Lunit’s 2024 acquisition of Volpara Health Technologies — completed May 22, 2024 per Lunit’s own media release — significantly expanded its U.S. breast screening software footprint and later merged under a unified Lunit brand as Lunit International.
What the company does
Lunit develops AI software that analyzes medical images for cancer detection and treatment-relevant biomarkers. Its Lunit INSIGHT products address chest X-ray nodule detection, mammography, and digital breast tomosynthesis; Lunit SCOPE products support pathology biomarker assessment such as PD-L1 scoring. Lunit sells to hospitals and screening networks globally, with regulatory clearances including FDA and CE marks on several products listed on its corporate timeline.
Following the completed Volpara acquisition, Lunit International commercializes integrated breast screening analytics alongside Lunit detection AI in the United States, Latin America, and Oceania — geographies where Volpara’s installed base and density data provide operational entry points independent of greenfield hospital sales cycles.
Lunit’s dual radiology-and-pathology portfolio lets health systems evaluate one vendor for screening triage and companion biomarker scoring, though procurement teams still separate PACS integration requirements from pathology LIS workflows when rolling out SCOPE products.
Who it serves
Lunit serves hospital radiology and screening departments, national health programs, and biopharmaceutical partners running imaging-based trials or companion diagnostic programs. Following the Volpara acquisition, Lunit International focuses on U.S., Latin America, and Oceania commercial operations where Volpara’s breast health data and customer base provide entry into mammography screening workflows.
National screening programs evaluating AI augmentation should model workflow changes for radiologist triage queues — AI savings materialize only when reading lists and reporting templates actually reorder work, not when algorithms run passively in background.
Company background
Lunit was founded in 2013 in Seoul, initially as CLDI before pivoting to medical imaging AI. The company completed an initial public offering on KOSDAQ and expanded through partnerships with Fujifilm, GE Healthcare, Guardant Health, and others listed on its about page timeline. Executive Chairman Anthony Seungwook Paek co-founded the company alongside CEO Brandon Beomseok Suh. Lunit signed a scheme implementation agreement to acquire Volpara in December 2023 and completed the transaction May 22, 2024 — a milestone Lunit described as completed, not pending, in its primary press release.
Lunit’s World Economic Forum Technology Pioneer history and repeated CB Insights Digital Health 150 recognition listed on its corporate timeline reflect sustained visibility in medical AI investor circles across multiple funding cycles before the Volpara deal.
Product and AI capabilities
Lunit’s AI models apply deep learning to radiology and pathology images, emphasizing clinically validated performance in screening and triage workflows. Integrating Volpara’s breast screening analytics with Lunit’s detection AI creates a broader breast-health ecosystem — a strategy CEO Brandon Suh articulated when Volpara began operating under the Lunit brand in November 2025. Lunit frames success not by clearance counts alone but by measurable impact on early detection and reduced care variability.
Cross-modality expansion — from chest X-ray triage to DBT and pathology PD-L1 — lets Lunit sell multiple products into the same hospital procurement relationship, amortizing integration costs that single-product vendors bear repeatedly.
Key developments
2013: Lunit founded in Seoul. May 22, 2024: Lunit completed acquisition of Volpara Health Technologies (Lunit media hub, primary source). November 6, 2025: Volpara rebranded as Lunit International under unified global identity (Lunit media hub). Brel cites acquisition completion only from Lunit primary releases, not third-party deal commentary.
Post-acquisition brand unification in November 2025 signals operational integration moving past legal close — a phase where product, support, and sales teams merge under one customer-facing identity.
Why it matters
Lunit matters because cross-border medical AI consolidation is reshaping who owns U.S. screening data assets. The Volpara deal gives Lunit installed breast-health infrastructure in markets where Korean vendors historically lacked density. For imaging AI buyers, Lunit also illustrates how public-market medical AI companies fund global expansion through M&A as well as organic R&D — a different growth model from many U.S. private pathology AI startups.
Screening program buyers should verify post-merger product roadmaps and support SLAs — acquisitions create short-term integration risk even when strategic rationale is sound. Lunit’s completed transaction status, documented in its May 2024 primary release, avoids the ambiguity Brel flags when profiles describe announced-but-unclosed deals as finished acquisitions.
Sector context
Lunit belongs in Brel’s AI in healthcare coverage under medical imaging AI, related to breast screening and radiology vendors and distinct from digital pathology platforms such as PathAI or Ibex Medical Analytics. Readers comparing consolidation risk should note Lunit’s completed Volpara acquisition versus announced-but-unclosed deals elsewhere in clinical AI.
Sources and references
Lunit Volpara acquisition completion release (May 22, 2024) and About Us page.
- Lunit — Volpara acquisition completed (lunit.io, May 22, 2024)
- Lunit — About Us (lunit.io)
Reviewed July 10, 2026. Brandon Beomseok Suh is CEO. Acquisition cited only from Lunit primary media-hub release.